
Global & Peru Cancer Therapeutics Market to 2031
Description
Peru faces a considerable cancer burden, with the National Institute of Health identifying cancer as one of the country's primary causes of death. According to global cancer statistics, approximately 69,849 new cancer cases and 34,976 related deaths were recorded in 2020. The same data also shows that around 4,636 new colorectal cancer cases were diagnosed across all age groups. The rising number of cancer diagnoses is driving demand for effective treatment options such as chemotherapy, immunotherapy, and targeted therapies. This growing need is encouraging pharmaceutical companies to develop and expand their therapeutic portfolios to better serve cancer patients.
To improve cancer care access, the Peruvian government has launched several strategic initiatives, including the implementation of a national cancer control plan through the Instituto Nacional de Enfermedades Neoplásicas (INEN). This plan emphasizes early detection, prevention, and comprehensive treatment. As of mid-2024, Peru continues to progress toward universal health coverage for cancer patients. International support from organizations such as the MD Anderson Cancer Center has been instrumental, with their participation in the imPACT Review mission and collaboration with local experts to enhance cancer prevention, diagnosis, and treatment strategies.
Additionally, in November 2023, Adium Pharma, a partner of PharmaMar, secured full regulatory approval from Peru’s Ministry of Health to commercialize Zepzelca (lurbinectedin). This therapy is intended for adult patients with metastatic small cell lung cancer (SCLC) who have experienced disease progression following platinum-based chemotherapy.
To improve cancer care access, the Peruvian government has launched several strategic initiatives, including the implementation of a national cancer control plan through the Instituto Nacional de Enfermedades Neoplásicas (INEN). This plan emphasizes early detection, prevention, and comprehensive treatment. As of mid-2024, Peru continues to progress toward universal health coverage for cancer patients. International support from organizations such as the MD Anderson Cancer Center has been instrumental, with their participation in the imPACT Review mission and collaboration with local experts to enhance cancer prevention, diagnosis, and treatment strategies.
Additionally, in November 2023, Adium Pharma, a partner of PharmaMar, secured full regulatory approval from Peru’s Ministry of Health to commercialize Zepzelca (lurbinectedin). This therapy is intended for adult patients with metastatic small cell lung cancer (SCLC) who have experienced disease progression following platinum-based chemotherapy.
Table of Contents
100 Pages
- 1. Introduction
- 1.1 Report Guidance
- 1.2 Market Segmentation
- 2. Executive Summary
- 2.1 Key Insights
- 3. Research Methodology
- 3.1 Secondary Research
- 3.2 Primary Research
- 3.2.1 Data Triangulation and Validation:
- 4. Peru Cancer Therapeutics Market Landscape
- 4.1 Overview
- 4.2 Ecosystem Analysis
- 4.2.1 List of Vendors in the Value Chain
- 5. Cancer Therapeutics Market Key Market Dynamics
- 5.1 Cancer Therapeutics Market – Key Market Dynamics
- 5.2 Market Drivers
- 5.3 Market Restraints
- 5.4 Market Opportunities
- 5.5 Future Trends
- 5.6 Impact of Drivers and Restraints
- 6. Peru Cancer Therapeutics Market – Analysis
- 6.1 Peru Cancer Therapeutics Market Revenue (US$ Million), 2021–2031
- 6.2 Peru Cancer Therapeutics Market Revenue and Forecast Analysis
- 7. Peru Cancer Therapeutics Market Analysis – by Therapy Types
- 7.1 Peru Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Therapy Types
- 8. Peru Cancer Therapeutics Market Analysis – by Indications
- 8.1 Peru Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Indications
- 9. Peru Cancer Therapeutics Market Analysis – by Distribution Channel
- 9.1 Peru Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Distribution Channel
- 10. Competitive Landscape
- 10.1 Heat Map Analysis by Key Players
- 10.1 Company Positioning and Concentration
- 11. Industry Landscape
- 11.1 Overview
- 11.2 Market Initiative
- 11.2 Partnerships and Collaborations
- 11.2 Other Developments
- 12. Company Profiles
- 12.1 Bristol-Myers Squibb Co
- 12.1. 1 Key Facts
- 12.1. 2 Business Description
- 12.1. 3 Products and Services
- 12.1. 4 Financial Overview
- 12.1. 5 SWOT Analysis
- 12.1. 6 Key Developments
- 12.2 AbbVie Inc
- 12.2. 1 Key Facts
- 12.2. 2 Business Description
- 12.2. 3 Products and Services
- 12.2. 4 Financial Overview
- 12.2. 5 SWOT Analysis
- 12.2. 6 Key Developments
- 12.3 Johnson & Johnson
- 12.3. 1 Key Facts
- 12.3. 2 Business Description
- 12.3. 3 Products and Services
- 12.3. 4 Financial Overview
- 12.3. 5 SWOT Analysis
- 12.3. 6 Key Developments
- 12.4 F. Hoffmann-La Roche Ltd
- 12.4. 1 Key Facts
- 12.4. 2 Business Description
- 12.4. 3 Products and Services
- 12.4. 4 Financial Overview
- 12.4. 5 SWOT Analysis
- 12.4. 6 Key Developments
- 12.5 Pfizer Inc
- 12.5. 1 Key Facts
- 12.5. 2 Business Description
- 12.5. 3 Products and Services
- 12.5. 4 Financial Overview
- 12.5. 5 SWOT Analysis
- 12.5. 6 Key Developments
- 12.6 AstraZeneca Plc
- 12.6. 1 Key Facts
- 12.6. 2 Business Description
- 12.6. 3 Products and Services
- 12.6. 4 Financial Overview
- 12.6. 5 SWOT Analysis
- 12.6. 6 Key Developments
- 12.7 Merck KGaA
- 12.7. 1 Key Facts
- 12.7. 2 Business Description
- 12.7. 3 Products and Services
- 12.7. 4 Financial Overview
- 12.7. 5 SWOT Analysis
- 12.7. 6 Key Developments
- 12.8 Novartis AG
- 12.8. 1 Key Facts
- 12.8. 2 Business Description
- 12.8. 3 Products and Services
- 12.8. 4 Financial Overview
- 12.8. 5 SWOT Analysis
- 12.8. 6 Key Developments
- 12.9 Astellas Pharma Inc
- 12.9. 1 Key Facts
- 12.9. 2 Business Description
- 12.9. 3 Products and Services
- 12.9. 4 Financial Overview
- 12.9. 5 SWOT Analysis
- 12.9. 6 Key Developments
- 12.10 Eli Lilly and Co
- 12.10. 1 Key Facts
- 12.10. 2 Business Description
- 12.10. 3 Products and Services
- 12.10. 4 Financial Overview
- 12.10. 5 SWOT Analysis
- 12.10. 6 Key Developments
- 13. Appendix
- 13.1 About Business Market Insights
- 13.2 List of Abbreviations
- TABLE OF TABLES
- Table 1. Peru Cancer Therapeutics Market Segmentation
- Table 2. List of Vendors
- Table 3. Peru Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million)
- Table 4. Peru Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million)
- Table 5. Peru Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Therapy Types
- Table 6. Peru Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Therapy Types
- Table 7. Peru Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Indications
- Table 8. Peru Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Indications
- Table 9. Peru Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Distribution Channel
- Table 10. Peru Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Distribution Channel
- Table 11. List of Abbreviations
- TABLE OF FIGURES
- Figure 1. Impact Analysis of Drivers and Restraints
- Figure 2. Peru Cancer Therapeutics Market Revenue, (US$ Million), 2021–2031
- Figure 3. Heat Map Analysis by Key Players
- Figure 4. Company Positioning and Concentration
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.